BWAY
HealthcareBrainsWay Ltd. · Medical - Devices · $590M
What is BrainsWay Ltd.?
BrainsWay is a medical technology company focused on noninvasive brain stimulation for mental health conditions. Operating across the United States, Europe, Israel, and other international markets, it targets one of healthcare's most underserved treatment areas.
BrainsWay develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation platform, which delivers targeted magnetic pulses to specific brain regions without surgery or anesthesia. The technology is cleared for multiple indications including major depressive disorder, obsessive-compulsive disorder, anxious depression, and smoking addiction. The company sells and leases its systems primarily to psychiatrists, hospitals, and specialized medical centers, generating revenue through device placements and ongoing treatment fees.
BrainsWay was founded in 2003 and is headquartered in Jerusalem, Israel.
- Deep TMS platform for major depressive disorder treatment
- OCD and anxious depression neurostimulation therapy
- Smoking cessation Deep TMS protocol
- Helmet-based coil technology for targeted brain region access
- Subscription and per-treatment revenue model for clinical partners
Is BWAY a Good Stock to Buy?
UQS Score rates BWAY as Good overall, reflecting a balanced profile with meaningful strengths and some areas of caution.
The Risk pillar stands out as the strongest element of BrainsWay's profile, suggesting the company carries a relatively contained risk profile compared to many small-cap healthcare peers. The Growth pillar also registers as Good, consistent with a company expanding its cleared indications and broadening its commercial footprint in a large, underpenetrated mental health market.
Both the Quality and Moat pillars sit at Neutral, indicating that durable competitive advantages and financial quality metrics have not yet reached a level that clearly separates BrainsWay from the broader peer group. The Valuation pillar is rated Elevated, meaning the current price reflects considerable optimism about future execution.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BWAY pay dividends?
No — BrainsWay Ltd. does not currently pay a dividend.
BrainsWay does not currently pay a dividend. For a growth-stage medical technology company, this is typical — available capital is directed toward expanding cleared indications, growing the installed device base, and funding clinical research rather than returning cash to shareholders. Income-focused investors should factor this into their assessment.
When does BWAY report earnings?
BrainsWay reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Growth pillar rating suggests BrainsWay has been making forward progress commercially, though results can vary quarter to quarter as the business scales its device placements and expands into new indications. Investors should monitor treatment volume trends and international market development as key signals.
For the most recent quarter's results and guidance, visit BrainsWay's official investor relations page.
What if I invested in BrainsWay Ltd.?
Based on BrainsWay Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BWAY Long-term Outlook
BrainsWay's Good Growth pillar and Strong Risk pillar together paint a picture of a company with meaningful upside potential that is navigating its expansion phase with relative discipline. The path forward hinges on continued regulatory clearances, deeper penetration of the psychiatric care market, and demonstrating scalable unit economics. The Elevated Valuation pillar is a reminder that much of this optimism may already be reflected in the share price, leaving limited room for execution missteps.
Growth drivers
- Expanding cleared indications across additional mental health and neurological conditions
- Growing installed base of Deep TMS systems in psychiatric clinics and hospitals
- International market development beyond the core US and Israeli markets
Key risks
- Elevated valuation leaves little margin for slower-than-expected commercial ramp
- Neutral Moat rating signals limited pricing power and potential for competitive pressure
- Reimbursement coverage decisions by insurers can materially affect adoption rates
BWAY vs Peers
BrainsWay operates in the broader medical device and neurostimulation space alongside a range of small-cap healthcare technology companies.
SI-BONE focuses on minimally invasive surgical implants for the sacropelvic anatomy, targeting orthopedic conditions rather than psychiatric or neurological disorders.
Cytek Biosciences develops advanced flow cytometry platforms for life science research, operating in a distinct segment of the healthcare technology market.
Tactile Systems provides pneumatic compression devices for chronic conditions like lymphedema, competing in the home-use medical device space rather than clinical neurostimulation.
Frequently Asked Questions
What does BrainsWay do?
BrainsWay develops noninvasive brain stimulation technology for mental health disorders. Its Deep Transcranial Magnetic Stimulation platform is cleared for conditions including major depressive disorder, OCD, anxious depression, and smoking addiction. The company sells and leases its systems to psychiatrists, hospitals, and medical centers globally.
Does BWAY pay dividends?
BrainsWay does not pay a dividend. As a growth-stage medical technology company, it reinvests available resources into clinical development, regulatory clearances, and commercial expansion rather than distributing cash to shareholders.
When does BWAY report earnings?
BrainsWay follows a standard quarterly earnings cadence for US-listed companies. Our data source does not cover specific upcoming dates. For the most current schedule, check BrainsWay's investor relations page directly.
Is BWAY a good stock to buy?
UQS Score rates BWAY as Good overall. The Risk pillar is Strong and Growth is rated Good, which are positive signals. However, the Valuation pillar is Elevated and both Quality and Moat are Neutral, meaning investors should weigh the growth opportunity against the current price. The full pillar breakdown is available to Pro members.
Is BWAY overvalued?
The UQS Valuation pillar for BWAY is rated Elevated, suggesting the market is pricing in a significant amount of future growth. This does not automatically make it a poor investment, but it does mean execution risk is higher — any shortfall in commercial progress could weigh on the stock.
How does BWAY compare to its competitors?
BrainsWay occupies a specialized niche in noninvasive neurostimulation for psychiatric conditions. Peers like SI-BONE, Cytek Biosciences, and Tactile Systems operate in adjacent but distinct medical device segments. BrainsWay's differentiation lies in its proprietary Deep TMS platform and its focus on mental health — a large and underserved market.
What is BWAY's market cap bracket?
BrainsWay is classified as a small-cap company. This means it carries higher volatility and liquidity risk than large- or mega-cap peers, but also retains more room for growth if its commercial strategy executes successfully.
Who founded BrainsWay?
BrainsWay was founded in 2003. Founding details and leadership history are publicly available through the company's official website and investor relations materials for those seeking a complete background.
Is BWAY a long-term quality investment?
From a long-term quality perspective, BrainsWay's Strong Risk pillar and Good Growth pillar are encouraging signals. However, the Neutral ratings on Quality and Moat suggest the company has not yet built the durable competitive advantages typically associated with the highest-quality long-term holdings. Monitoring progress on these dimensions over time is worthwhile.
What is the main competitive advantage of BrainsWay?
BrainsWay's primary differentiator is its proprietary Deep TMS helmet-coil technology, which allows targeting of deeper brain structures than conventional TMS devices. Multiple FDA clearances across distinct psychiatric indications also create a degree of clinical credibility that newer entrants would need time to replicate.
What sector does BWAY belong to?
BrainsWay operates in the Healthcare sector, specifically within medical devices and neurostimulation technology. Its focus on psychiatric and neurological conditions places it at the intersection of medical hardware and mental health treatment — a segment attracting growing clinical and investor attention.
Is BWAY a growth stock or value stock?
Based on its UQS profile, BWAY leans toward the growth side. The Growth pillar is rated Good and the Valuation pillar is Elevated, which together suggest the market is assigning a premium for anticipated future expansion rather than current earnings power.
Unlock Full BWAY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial quality and moat metrics
- ✓Compare BWAY against sector peers side by side
- ✓Track valuation changes with updated scoring
- ✓Get the full analyst-style risk and growth assessment
- ✓Screen small-cap healthcare stocks by pillar strength
Pro Analysis
BWAY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 53.3 | 45.7 | 41.0 | 74.3 | 84.4 | 27.7 | 0.0 |
| May 21, 2026 | 53.3 | 45.7 | 41.0 | 74.3 | 84.4 | 27.2 | -0.1 |
| May 19, 2026 | 53.4 | 45.7 | 41.0 | 74.3 | 84.4 | 28.1 | +0.1 |
| May 16, 2026 | 53.3 | 45.7 | 41.0 | 74.3 | 84.4 | 27.7 | +0.3 |
| May 15, 2026 | 53.0 | 45.7 | 41.0 | 74.3 | 84.4 | 25.4 | 0.0 |
| May 14, 2026 | 53.0 | 45.7 | 41.0 | 74.3 | 84.4 | 25.5 | +0.1 |
| May 12, 2026 | 52.9 | 45.7 | 41.0 | 74.3 | 84.4 | 24.6 | +0.1 |
| May 11, 2026 | 52.8 | 45.7 | 41.0 | 74.3 | 84.4 | 24.1 | +4.3 |
| May 10, 2026 | 48.5 | 37.3 | 41.0 | 74.3 | 84.4 | 9.7 | -0.1 |
| May 8, 2026 | 48.6 | 37.3 | 41.0 | 74.3 | 84.4 | 9.9 | -4.3 |
BWAY — Pillar Breakdown
Quality
— 45.7/100 (25%)BrainsWay Ltd. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 74.3/100 (20%)BrainsWay Ltd. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 84.4/100 (15%)BrainsWay Ltd. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 27.7/100 (15%)BrainsWay Ltd. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 41/100 (25%)BrainsWay Ltd. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BWAY.
Score Composition
Financial Data
More Stock Analysis
How is the BWAY UQS Score Calculated?
The UQS (Unified Quality Score) for BrainsWay Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BrainsWay Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BrainsWay Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.